Solvay is manufacturer of speciality and bulk chemicals, polymers and processed plastics. It has two business sectors; Chemicals and Plastics.
The company is now strategically focussed on the following areas: growth in chemicals and selected plastic areas; innovation; and increasing its presence in Asia, the Americas and eastern Europe.
Solvay says it is benefiting from the results of a group-wide innovation initiative, which is bringing new product, processes and applications, as well as improvements at all levels across the company.
The company says that it needs to act faster to position itself in growth markets, in particular in Asia. It also believes that it needs to be ‘fearless in divesting and investing’ where it can.
In February 2010, Solvay completed the sale of its pharmaceutical business to Abbott Laboratories. The deal was first announced in September 2009. For more on this please see Abbott completes Solvay pharmaceuticals acquisition on ICIS news.
With headquarters in Brussels, Belgium, Solvay employs some 16,800 people in 40 countries and had consolidated sales of €7bn in 2010.
Chairman: Alois Michielsen
Vice chairman: Denis Solvay
Board member: Christian Jourquin
Board member: Bernard de LaguicheBoard member: Jean-Marie SolvayBoard member: Chevalier Guy de Selliers de MoranvilleBoard member: Nicolas BoëlBoard member: Whitson SadlerBoard member: Jean van ZeebroeckBoard member: Jean-Martin FolzBoard member: Karel Van MiertBoard member: Bernhard ScheubleBoard member: Anton van RossumBoard member: Charles Casimir-LambertBoard member: Hervé Coppens d'EeckenbruggeBoard member: Petra Mateos-Aparicio Morales
(Updated April 2010)
Solvay SA Rue du Prince Albert 33 B-1050 Bruxelles Belgium
Tel: +32 2 509 6111 Fax: +32 2 509 6617 Email: email@example.com
Solvay operates in pharmaceuticals, chemicals and plastics. In 1861, Ernest Solvay developed a revolutionary ammonia-soda process for producing sodium carbonate. The Solvay group was founded in 1863 to exploit this process.
More about Solvay Structure
The “change strategy” that was first launched in 1998 focused on two major elements: strengthening the company’s leadership in all of its activities and accelerating the development of the pharmaceuticals sector and its specialties products. These objectives are said to have been met and the company will now strategically focus on the following three areas: growth in pharmaceuticals, chemicals and selected plastic areas; innovation; and increasing its presence in Asia, the Americas and Eastern Europe. (Edited from annual report and company website). ICIS also provides you with key financial data listed in table form.
More about Solvay Strategy & Financial Highlights
Get news on Solvay plus the latest chemical news, information, data, market movements and analysis
in one place with ICIS news
Find details on other chemical companies and suppliers with
ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.
Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database
INSIGHT: Outlook has to remain cautious in low growth environment
“Production of plastic resins was flat in April while production of specialty chemicals fell."
VIDEO: ICIS Europe Lunchtime Bulletin 23 May 2013